Skip to main content

Limbal Stem Cell Deficiency

2
Pipeline Programs
2
Companies
3
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

RHEACELL
RHEACELLGermany - Heidelberg
1 program
1
LSC2Phase 1/21 trial
Active Trials
NCT03549299Unknown16Est. Sep 2023
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
2 programs
1
CSB-001 Ophthalmic Solution 0.1%Phase 11 trial
Non-interventionalN/A1 trial
Active Trials
NCT07636590Recruiting500Est. Mar 2028
NCT06452316Recruiting75Est. Dec 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
RHEACELLLSC2
BioTherapeutics IncCSB-001 Ophthalmic Solution 0.1%
BioTherapeutics IncNon-interventional

Clinical Trials (3)

Total enrollment: 591 patients across 3 trials

NCT03549299RHEACELLLSC2

Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD

Start: Jul 2019Est. completion: Sep 202316 patients
Phase 1/2Unknown
NCT06452316BioTherapeutics IncCSB-001 Ophthalmic Solution 0.1%

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

Start: May 2024Est. completion: Dec 202775 patients
Phase 1Recruiting
NCT07636590BioTherapeutics IncNon-interventional

Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

Start: May 2026Est. completion: Mar 2028500 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 591 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.